China-to-Malaysia Market Entry: Five Steps from Zero to Registration

1. Key takeaways

The route from a Chinese manufacturing site to a Malaysian registration certificate has five stages, and none of them can be compressed by working harder on the dossier alone. The device is first classified under the First Schedule into Class A, B, C or D. A local licence-holding entity is then identified, which means an authorised representative holding an establishment licence. For Class B, Class C and Class D devices, a conformity assessment body completes the assessment. The application is then submitted to the MDA through MeDC@St. After the certificate is issued, the post-market obligations begin, and the import permit requirement, mandatory from 1 July 2027, becomes part of the planning horizon.

• Step one is classification under the First Schedule into one of the four classes, which fixes the route and the fee tier for everything that follows.
• Step two is the local licence holder: an authorised representative (AR) holding an establishment licence (EL), which is the entity that applies.
• Step three is conformity assessment by a CAB, which applies to Class B, Class C and Class D devices.
• Step four is submission of the registration to the MDA through MeDC@St.
• Step five is post-market compliance after certification, with the import permit becoming mandatory from 1 July 2027.
• A foreign manufacturer cannot register directly; the AR holds the EL and stands as the applicant of record.

2. Legal basis

The five stages map onto specific provisions. Registration is required by Act 737, with Sections 5 and 7 governing the application and its determination, and Section 15 governing the establishment licence that the applicant must hold. The content of the conformity assessment is set by the Third Schedule to the Medical Device Regulations 2012, which also carries the EPSP in Appendix 1 and the CSDT template in Appendix 2. The verification pathway available to holders of recognised foreign approvals comes from Circular Letter MDA No. 1/2025. The import permit requirement is the subject of the MDA announcement Update on the Enforcement Date for Medical Device Import Permit, dated 1 December 2025, which extended the mandatory date to 1 July 2027.

The overall cycle is estimated in the market at about 2 to 3 months for Class A, about 4 to 6 months for Class B and about 6 to 12 months for Class C and Class D. This is a practical estimate drawn from industry experience and not an official commitment. The figures depend on the completeness of the dossier, the scheduling of the CAB and the number of review rounds the MDA requires. A file that is complete at first submission and a file that is corrected over three rounds can differ by more than the difference between two adjacent classes, which is why the timeline is better managed through dossier quality than through pressure on the review.

The prohibition on direct registration by a foreign manufacturer is structural rather than procedural. The applicant must hold an EL, and the EL is held by a Malaysian establishment. The AR is therefore not an optional intermediary but the legal person in whose name the certificate is granted, and the arrangement between the manufacturer and the AR is the foundation on which the rest of the project rests.

3. Expert insights

The two costs most often underestimated in a Malaysian market entry plan are the CAB conformity assessment fee and the annual AR service fee. The CAB fee varies substantially between bodies and has to be quoted individually rather than estimated from a schedule, and the AR fee recurs annually for as long as the registration is maintained. The official fees, by contrast, are published and transparent, which creates a misleading impression that the total cost of entry is knowable from the schedule alone. Budgets built only on official fees tend to be optimistic in a way that becomes visible at the worst moment, when the dossier is ready and the assessment has to be commissioned.

The second insight concerns partner risk. The AR holds the EL, and the EL depends on the AR maintaining its own quality system credentials, including its GDPMD certificate. If that certificate lapses, the registrations held through the AR do not simply become harder to use; the processes attached to them stall together. The EL validity check is therefore not a due diligence formality but a continuity control, and it belongs at the front of the project, before the AR agreement is signed, rather than after the first submission has been filed.

The third insight is about sequencing rather than speed. Malaysia offers a framework aligned with the ASEAN Medical Device Directive, costs that are lower than those of the European or United States markets, and a submission process conducted in English, which removes a translation layer that exists in several neighbouring jurisdictions. For a manufacturer that already holds a CE or FDA approval, the verification pathway can shorten the assessment stage appreciably. The value of these advantages, however, depends on the AR and the classification being settled before the dossier is written, because a dossier built for the wrong applicant or the wrong class has to be rebuilt rather than corrected.

4. Practical recommendations

• Fix the classification first, in writing, with the First Schedule rule cited for each product, before any commercial commitment to a launch date.
• Screen candidate ARs on the validity of the EL and the GDPMD certificate, verify both in official records, and put the verification in writing before signing.
• Write the AR agreement so that it addresses what happens if the EL lapses, including the fate of the registrations held through the entity.
• Obtain CAB quotations early and individually, and budget the annual AR service fee as a recurring cost rather than a one-off.
• Plan the file for a single complete submission, using the Third Schedule as the checklist, since review rounds are the main variable in the timeline.
• Add the import permit requirement to the launch plan now, treating 1 July 2027 as a fixed date in the project schedule rather than a future item.

5. Verification checklist

• □ Act 737 Sections 5, 7 and 15 confirmed against the published text (pending verification).
• □ Third Schedule to the Medical Device Regulations 2012 reviewed for the conformity assessment elements (pending verification).
• □ Circular Letter MDA No. 1/2025 read for the verification pathway conditions (pending verification).
• □ MDA announcement Update on the Enforcement Date for Medical Device Import Permit, 1 December 2025, confirmed as extending the mandatory date to 1 July 2027 (pending verification).
• □ AR establishment licence and GDPMD certificate checked for validity on the date of the agreement (pending verification).
• □ CAB quotation obtained in writing for the class actually claimed (pending verification).

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Malaysia. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the MDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com